Canada's Price Negotiators On Where Firms Go Wrong
This article was originally published in Scrip
If your company wants to sell its products on Canada's publicly funded drug plans, then it will likely have to do business with the pan-Canadian Pharmaceutical Alliance. This is the body that negotiates drug prices for provincial and territorial drug plans and which has ensured that product listing agreements have become a prerequisite for securing drug funding across the Canadian market. The pCPA's Brad Alyward, from Nova Scotia's Department for Health and Wellness, and Sherry O'Quinn*, from the Ontario Public Drug Programs Division, spoke to Scrip about the perils of trying to charge too high a price and the future of evidence generation-based agreements.
You may also be interested in...
Worried about its relevance to payers, Canada's drug price regulator is consulting on how it should modernize its guidelines. The result could be more pressure on regulated prices.
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.